Current Trials



S1703 - (opened 4/2019): Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer.
NRG-BR007 - (opened 8/2021): A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive , HER2- Negative, Oncotype Recurrence Score
A021703 SOLARIS - (opened 11/2019): Randomized Double-blind Phase III trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer.
EA3161 - (opened 02/2020) A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA.

ALCHEMIST Trials - (opened 8/2016):
  • A151216 (ALCHEMIST-Screen) Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial.
  • E4512 (ALCHEMIST-ALK) Phase III Double-blind Trial for Surgically Resected Early Stage NSCLC: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein.

EA5181 - (opened 11/2020): Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC.

Connect Myeloid - (opened 6/2013): The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.
Multiple Site
LP-CT-PALO - (opened 8/2022): A Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy.
EA2186 -  (opened 9/2021): Randomized Phase II Study of Gemcitabine and Nab- Paclitaxel Compared with 5- Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)


DAPA ACT HF - (opened 9/2020): Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure- Thrombolysis in Myocardial Infarction 68 (DAPA ACR HF- TIMI 68).
SOLVE CRT - (opened 2/2020): Stimulation of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non- Responders and Previously Untreatable Patients Study
CHAMPTION AF - (opened 2/2021): WATCHMAN FLX versus NOAC for EMbolicProtectION in the Management of Patients with Non- Valvular Atrial Fibrillation (CHAMPION-AF).

For More Information: 
If you would like additional information about the Center for Research, please send your name, company or practice name, address and telephone number to the following address:
Watson Clinic Center for Research
1600 Lakeland Hills Blvd
Lakeland, FL 33805
Attn: Noreen McGowan, BSN, CCRC, Director
Phone 863-688-6826 · FAX 863-688-5842
Please indicate which of the following type(s) of information you would like:
  • Additional information about current protocols
  • Center for Research grants
  • Contributing to Center for Research funding
  • Involvement in Center for Research protocols

Return to Clinical Trials Page